Emergent Biosolutions
EBS
236 hedge funds and large institutions have $2.43B invested in Emergent Biosolutions in 2019 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 76 increasing their positions, 96 reducing their positions, and 22 closing their positions.
3% more capital invested
Capital invested by funds: $2.35B → $2.43B (+$76.1M)
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
0.04% less ownership
Funds ownership: 87.16% → 87.12% (-0.04%)
3% less funds holding
Funds holding: 244 → 236 (-8)
21% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 96
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
78% less call options, than puts
Call options by funds: $582K | Put options by funds: $2.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$16.3M |
| 2 |
EARNEST Partners
Atlanta,
Georgia
|
+$15.7M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$15.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.7M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.1M |
| 2 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$16.2M |
| 3 |
Renaissance Technologies
New York
|
-$11.9M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$10.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$10.1M |
EBS Hedge Fund Activity: Q4 2019 in Review
236 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2019, worth a combined $2.43B — up 3.2% from $2.35B a quarter earlier.
Fund positioning in EBS was balanced in Q4 2019: 22 funds opened new positions, 22 closed out, 76 added to existing stakes and 96 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $16.3M. The largest seller was Millennium Management, cutting an estimated $19.1M.
- 236 institutional investors held Emergent Biosolutions (EBS) as of Q4 2019, down from 244 in Q3 2019.
- Funds reported $2.43B of Emergent Biosolutions stock for Q4 2019, up 3.2% quarter-over-quarter.
- 22 funds opened new Emergent Biosolutions positions in Q4 2019 and 22 closed out, a net change of 0 holders.
- The largest Emergent Biosolutions buyer in Q4 2019 was Acadian Asset Management, an estimated $16.3M added.
- The largest Emergent Biosolutions seller in Q4 2019 was Millennium Management, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2019.